Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update.

Autor: Cooke GS; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK; Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA. Electronic address: g.cooke@imperial.ac.uk., Flower B; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK., Cunningham E; The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia., Marshall AD; The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia., Lazarus JV; CUNY Graduate School of Public Health and Health Policy, New York, NY, USA; Barcelona Institute for Global Health, Hospital Clinic, University of Barcelona, Barcelona, Spain., Palayew A; Department of Epidemiology, University of Washington, Seattle, WA, USA., Jia J; Liver Research Centre, Beijing Friendship Hospital, Capital Medical University, Beijing, China., Aggarwal R; Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India., Al-Mahtab M; Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh., Tanaka Y; Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan., Jeong SH; Department of Internal Medicine, Seoul National University Bundang Hospital, College of Medicine, Seoul National University, Seongnam, South Korea., Poovorawan K; Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Thailand., Waked I; Hepatology Department, National Liver Institute, Shibin El Kom, Egypt., Hiebert L; Coalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, GA, USA., Khue PM; Faculty of Public Health, Haiphong University of Medicine and Pharmacy, Haiphong, Viet Nam., Grebely J; The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia., Alcantara-Payawal D; Department of Internal Medicine, Fatima University Medical Center, Valenzuela, Philippines; Committee on Hepatology, Section of Gastroenterology, Cardinal Santos Medical Center, San Juan, Philippines., Sanchez-Avila JF; Global Health and Emerging Diseases Investigation Group, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey Monterrey, Mexico., Mbendi C; Service of Gastroenterology, Internal Medicine, University Clinic of Kinshasa, Faculty of Medicine, University of Kinshasa, Kinshasha, DR Congo., Muljono DH; Ministry of Health, Jakarta, Indonesia; Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia; Indonesian Academy of Sciences, Jakarta, Indonesia., Lesi O; Gastroenterology and Hepatology Unit, College of Medicine, University of Lagos and Lagos University Teaching Hospital, Lagos, Nigeria., Desalegn H; Department of Internal Medicine, St Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia., Hamid S; Clinical Trials Unit, Aga Khan University, Karachi, Pakistan., de Araujo A; Universidade Federal do Rio Grande do Sul, Gastroenterology and Hepatology Unit of Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil., Cheinquer H; Universidade Federal do Rio Grande do Sul, Gastroenterology and Hepatology Unit of Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil., Onyekwere CA; Deparment Of Medicine, Lagos State University College of Medicine, Lagos, Nigeria., Malyuta R; HIV/AIDS Programme Group, UNICEF, New York, NY, USA., Ivanchuk I; Department of Viral Hepatitis Control at National Institute of Public Health, Kyiv, Ukraine., Thomas DL; Divison of Infectious Diseases, John Hopkins School of Medicine, Baltimore, MD, USA., Pimenov N; National Medical Research Center of Tuberculosis and Infectious Diseases, Moscow, Russia., Chulanov V; I M Sechenov First Moscow State Medical University, Moscow, Russia., Dirac MA; Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA; Department of Family Medicine, University of Washington, Seattle, WA, USA., Han H; Department of Epidemiology, University of Washington, Seattle, WA, USA; Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA., Ward JW; Coalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, GA, USA; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Jazyk: angličtina
Zdroj: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2024 Apr; Vol. 9 (4), pp. 346-365. Date of Electronic Publication: 2024 Feb 15.
DOI: 10.1016/S2468-1253(23)00321-7
Abstrakt: The top 20 highest burdened countries (in disability-adjusted life years) account for more than 75% of the global burden of viral hepatitis. An effective response in these 20 countries is crucial if global elimination targets are to be achieved. In this update of the Lancet Gastroenterology & Hepatology Commission on accelerating the elimination of viral hepatitis, we convene national experts from each of the top 20 highest burdened countries to provide an update on progress. Although the global burden of diseases is falling, progress towards elimination varies greatly by country. By use of a hepatitis elimination policy index conceived as part of the 2019 Commission, we measure countries' progress towards elimination. Progress in elimination policy has been made in 14 of 20 countries with the highest burden since 2018, with the most substantial gains observed in Bangladesh, India, Indonesia, Japan, and Russia. Most improvements are attributable to the publication of formalised national action plans for the elimination of viral hepatitis, provision of publicly funded screening programmes, and government subsidisation of antiviral treatments. Key themes that emerged from discussion between national commissioners from the highest burdened countries build on the original recommendations to accelerate the global elimination of viral hepatitis. These themes include the need for simplified models of care, improved access to appropriate diagnostics, financing initiatives, and rapid implementation of lessons from the COVID-19 pandemic.
Competing Interests: Declaration of interests GSC is supported in part by the Biomedical Research Centre of Imperial College NHS Trust. In the last 36 months, IW has received grant funding from AbbVie, Arena, AstraZeneca, Novartis, and Pharco. JG has received funding from AbbVie, bioLytical, Camurus, Cepheid, Gilead, Hologic, and Indivior. YT has received funding from Fujirebio, Sysmex, AbbVie, GlaxoSmithKline, and Gilead Sciences. JVL acknowledges grants and speaker fees from AbbVie, Gilead Sciences, Merck Sharp and Dohme, and Roche Diagnostics to his institution; speaker fees from Echosens, Janssen, Novo Nordisk, and ViiV; consulting fees from GSK and Novavax; and support to ISGlobal (grant CEX2018-000806-S) funded by MCIN/AEI/10.13039/501100011033, and the Generalitat de Catalunya through the CERCA programme, outside of the submitted work. DLT has provided expert testimony for Merck; has worked on diagnostics with Abbott. Through the Taskforce for Global Health, LH and JWW have received support for the Coalition for Global Hepatitis Elimination from governmental, philanthropic, individual, and industry partners (Abbott Laboratories, AbbVie, Cepheid, Gilead Sciences, Merck, Pharco, Roche Diagnostics, Siemens, VBI Vaccines, and Zydus-Cadila). DA-P has received payment from Viatris and Inogen Pharmaceutical for delivering presentations at conferences. ADM received AU$300 in 2021 to review a grant for the National Medical Research Council, Singapore. HC received lecture fees from Gilead Sciences. A portion of MAD's compensation comes from the Bill & Melinda Gates Foundation Global Public Goods Grant through its funding of work done for the Global Burden of Diseases, Injuries & Risk Factors study. All other authors declare no competing interests.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE